Specifically, Bracco is developing an application that would utilize its microbubble platform for treating chronic dysfunctional diseases related to lipid metabolism, according to the company. The research project resulted from a recent agreement with SonoGene, a start-up that's developing platforms for the therapeutic delivery of genes and pharmaceuticals using ultrasound-triggered microbubble delivery systems, Bracco said.
The vendor said it plans to cooperate closely on the project with ultrasound contrast luminary Dr. Steven Feinstein, a professor of medicine at Rush University Medical Center in Chicago and co-president of the International Contrast Ultrasound Society. The new experimental activities are now underway at Bracco's R&D center in Geneva.
Copyright © 2018 AuntMinnie.com